Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Ovid Therapeutics (NASDAQ: OVID), a biopharmaceutical company focused on developing medicines for brain conditions, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's President and Chief Operating Officer, Meg Alexander, will deliver a presentation on Monday, April 7, 2025, at 8:45 AM ET.
Investors and interested parties can access the live webcast through the Events & Presentations section at investors.ovidrx.com. A replay will remain available on the company's website for approximately 30 days after the presentation.
Ovid Therapeutics (NASDAQ: OVID), un'azienda biofarmaceutica focalizzata sullo sviluppo di farmaci per condizioni cerebrali, ha annunciato la sua partecipazione alla 24ª Conferenza Sanitaria Virtuale Annuale di Needham.
Il Presidente e Chief Operating Officer dell'azienda, Meg Alexander, terrà una presentazione lunedì 7 aprile 2025, alle 8:45 AM ET.
Gli investitori e le parti interessate possono accedere alla diretta streaming attraverso la sezione Eventi e Presentazioni su investors.ovidrx.com. Una registrazione rimarrà disponibile sul sito web dell'azienda per circa 30 giorni dopo la presentazione.
Ovid Therapeutics (NASDAQ: OVID), una empresa biofarmacéutica centrada en el desarrollo de medicamentos para condiciones cerebrales, ha anunciado su participación en la 24ª Conferencia Virtual Anual de Salud de Needham.
La Presidenta y Directora de Operaciones de la empresa, Meg Alexander, realizará una presentación el lunes 7 de abril de 2025, a las 8:45 AM ET.
Los inversores y partes interesadas pueden acceder a la transmisión en vivo a través de la sección de Eventos y Presentaciones en investors.ovidrx.com. Una grabación estará disponible en el sitio web de la empresa durante aproximadamente 30 días después de la presentación.
오비드 테라퓨틱스 (NASDAQ: OVID), 뇌 질환 치료제를 개발하는 바이오제약 회사가 제24회 니드햄 연례 가상 헬스케어 컨퍼런스에 참여한다고 발표했습니다.
회사의 사장 겸 COO인 메그 알렉산더가 2025년 4월 7일 월요일 오전 8시 45분 ET에 발표를 진행할 예정입니다.
투자자 및 관심 있는 분들은 investors.ovidrx.com의 이벤트 및 발표 섹션을 통해 실시간 웹캐스트에 접근할 수 있습니다. 발표 후 약 30일 동안 회사 웹사이트에서 다시보기 서비스를 이용할 수 있습니다.
Ovid Therapeutics (NASDAQ: OVID), une entreprise biopharmaceutique spécialisée dans le développement de médicaments pour les affections cérébrales, a annoncé sa participation à la 24e Conférence Virtuelle Annuelle de Santé de Needham.
La Présidente et Directrice des Opérations de l'entreprise, Meg Alexander, fera une présentation le lundi 7 avril 2025, à 8h45 ET.
Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct via la section Événements & Présentations sur investors.ovidrx.com. Un enregistrement restera disponible sur le site de l'entreprise pendant environ 30 jours après la présentation.
Ovid Therapeutics (NASDAQ: OVID), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Medikamenten für Gehirnerkrankungen konzentriert, hat seine Teilnahme an der 24. jährlichen virtuellen Gesundheitskonferenz von Needham bekannt gegeben.
Die Präsidentin und Chief Operating Officer des Unternehmens, Meg Alexander, wird am Montag, den 7. April 2025, um 8:45 Uhr ET eine Präsentation halten.
Investoren und Interessierte können die Live-Übertragung über den Bereich Veranstaltungen & Präsentationen auf investors.ovidrx.com abrufen. Eine Wiederholung wird etwa 30 Tage nach der Präsentation auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 8:45 AM. ET.
A live webcast of the Needham Virtual Healthcare Conference presentation can be accessed through the Events & Presentations section of the company’s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company’s website following the live presentation for approximately 30 days.
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small molecule candidates that have the potential to modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, and a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders; and OV888/GV101, a highly selective ROCK2 inhibitor, for undisclosed neurovascular and neuro-inflammatory conditions. For more information about these and other Ovid research programs, please visit www.ovidrx.com.
Investor Relations:
Victoria Fort
202-361-445
vfort@ovidrx.com
FAQ
When is Ovid Therapeutics (OVID) presenting at the Needham Healthcare Conference 2025?
How can investors watch Ovid Therapeutics' (OVID) Needham Conference presentation?
Who will represent Ovid Therapeutics (OVID) at the 2025 Needham Healthcare Conference?
How long will Ovid Therapeutics' (OVID) Needham Conference presentation replay be available?
